Sugi Predict

Sugi Predict / Compounds / SCHEMBL296996

SCHEMBL296996

SCHEMBL296996

CN(C)c1ccc(S(=O)(=O)n2ccc(C=CC(=O)NO)c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 19/20 0.73
▸ HDAC6 Q9UBN7 16/20 0.73
▸ HDAC8 Q9BY41 13/20 0.72
▸ HDAC3 O15379 13/20 0.72
▸ HDAC2 Q92769 15/20 0.51
▸ HDAC10 Q969S8 12/20 0.51
▸ HDAC11 Q96DB2 12/20 0.51
▸ HDAC9 Q9UKV0 12/20 0.51
▸ HDAC4 P56524 11/20 0.51
▸ HDAC7 Q8WUI4 11/20 0.51
▸ HDAC5 Q9UQL6 11/20 0.51
▸ KDM1A O60341 1/20 0.47
▸ HSD17B3 P37058 1/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ EGFR P00533 1/20 0.44
▸ ERBB2 P04626 1/20 0.44
▸ INSR P06213 1/20 0.44
▸ PDGFRB P09619 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296995 1.00 HDAC1 (0.73) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL297011 0.88 HDAC1 (0.57) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL297010 0.88 HDAC1 (0.57) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL28632867 0.86 HDAC1 (0.71) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3141696 0.86 HDAC1 (0.62) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3141682 0.86 HDAC1 (0.62) HDAC1HDAC6HDAC8HDAC3HDAC2
Resminostat SCHEMBL295541 0.85 HDAC1 (1.00) HDAC1HDAC6HDAC8HDAC3HDAC2
Resminostat SCHEMBL295540 0.85 HDAC1 (1.00) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL3052736 0.84 HDAC1 (0.56) HDAC1HDAC6HDAC8HDAC3HDAC2
Resminostat SCHEMBL1887874 0.84 HDAC1 (1.00) HDAC1HDAC6HDAC8HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969401-B2 Sulfonylpyrroles 4SC AG (DE) 2015-03-03 — — US claimed
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 — — EP claimed
US-20130079347-A1 NOVEL SULFONYLPYRROLES ALTANA PHARMA AG (DE) 2013-03-28 — — US claimed
US-8399505-B2 Sulfonylpyrroles 4SC AG (DE) 2013-03-19 — — US claimed
US-7842820-B2 Sulfonylpyrroles 4SC AG (DE) 2010-11-30 — — US claimed
US-20100261761-A1 Novel Sulfonylpyrroles MAIER THOMAS 2010-10-14 — — US claimed
US-20070184979-A1 Novel sulfonylpyrroles ALTANA PHARMA AG (DE) 2007-08-09 — — US claimed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 — — EP claimed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 — — WO claimed
US-11541027-B2 Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases DEL MAR PHARMACEUTICALS (BC) LTD. (CA) 2023-01-03 — — US disclosed
CN-106659765-B Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer 德玛医药 2021-08-13 — — CN disclosed
EP-3125920-B1 DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER DEL MAR PHARMACEUTICALS (CA) 2020-12-23 — — EP disclosed
US-20190269646-A9 USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES DEL MAR PHARMACEUTICALS (BC) LTD. (CA) 2019-09-05 — — US disclosed
WO-2019043176-A2 HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY 4SC AG (DE) 2019-03-07 — — WO disclosed
EP-1928872-A1 NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES Nycomed GmbH (DE) 2008-06-11 — — EP disclosed
US-20070184979-A1 Novel sulfonylpyrroles ALTANA PHARMA AG (DE) 2007-08-09 — — US disclosed
WO-2007039404-A1 NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES NYCOMED GMBH (DE) 2007-04-12 — — WO disclosed
WO-2007039403-A1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS NYCOMED GMBH (DE) 2007-04-12 — — WO disclosed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 — — EP disclosed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070184979-A1 Novel sulfonylpyrroles HDAC1, HDAC4, HDAC3 HDAC1 1/4885HDAC6 8/4885HDAC8 9/4885
US-20100261761-A1 Novel Sulfonylpyrroles HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885
US-20190269646-A9 USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES DNMT1, MGMT, DCK HDAC1 154/4885HDAC6 1422/4885HDAC8 332/4885
US-20130079347-A1 NOVEL SULFONYLPYRROLES HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885
US-11541027-B2 Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases DNMT1, MGMT, DCK HDAC1 154/4885HDAC6 1422/4885HDAC8 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.